These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 30864729)

  • 1. PD‑L1 promotes head and neck squamous cell carcinoma cell growth through mTOR signaling.
    Zheng A; Li F; Chen F; Zuo J; Wang L; Wang Y; Chen S; Xiao B; Tao Z
    Oncol Rep; 2019 May; 41(5):2833-2843. PubMed ID: 30864729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of melatonin and rapamycin for head and neck cancer therapy: Suppression of AKT/mTOR pathway activation, and activation of mitophagy and apoptosis via mitochondrial function regulation.
    Shen YQ; Guerra-Librero A; Fernandez-Gil BI; Florido J; García-López S; Martinez-Ruiz L; Mendivil-Perez M; Soto-Mercado V; Acuña-Castroviejo D; Ortega-Arellano H; Carriel V; Diaz-Casado ME; Reiter RJ; Rusanova I; Nieto A; López LC; Escames G
    J Pineal Res; 2018 Apr; 64(3):. PubMed ID: 29247557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting mTOR-CCL20 Signaling May Improve Response to Docetaxel in Head and Neck Squamous Cell Carcinoma.
    Chou MH; Chuang HC; Lin YT; Tsai MH; Kao YH; Lin IC; Huang TL; Fang FM; Chien CY
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33802643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A retroinhibition approach reveals a tumor cell-autonomous response to rapamycin in head and neck cancer.
    Amornphimoltham P; Patel V; Leelahavanichkul K; Abraham RT; Gutkind JS
    Cancer Res; 2008 Feb; 68(4):1144-53. PubMed ID: 18281490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting mTOR by CZ415 Inhibits Head and Neck Squamous Cell Carcinoma Cells.
    Xie J; Li Q; Ding X; Gao Y
    Cell Physiol Biochem; 2018; 46(2):676-686. PubMed ID: 29621758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial.
    Day TA; Shirai K; O'Brien PE; Matheus MG; Godwin K; Sood AJ; Kompelli A; Vick JA; Martin D; Vitale-Cross L; Callejas-Varela JL; Wang Z; Wu X; Harismendy O; Molinolo AA; Lippman SM; Van Waes C; Szabo E; Gutkind JS
    Clin Cancer Res; 2019 Feb; 25(4):1156-1164. PubMed ID: 30420444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck.
    Amornphimoltham P; Patel V; Sodhi A; Nikitakis NG; Sauk JJ; Sausville EA; Molinolo AA; Gutkind JS
    Cancer Res; 2005 Nov; 65(21):9953-61. PubMed ID: 16267020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of PD‑L1 expression by standard therapy in head and neck cancer cell lines and exosomes.
    Affolter A; Liebel K; Tengler L; Seiz E; Tiedtke M; Azhakesan A; Schütz J; Theodoraki MN; Kern J; Ruder AM; Fleckenstein J; Weis CA; Bieback K; Kramer B; Lammert A; Scherl C; Rotter N; Ludwig S
    Int J Oncol; 2023 Sep; 63(3):. PubMed ID: 37503786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved clearance during treatment of HPV-positive head and neck cancer through mTOR inhibition.
    Coppock JD; Wieking BG; Molinolo AA; Gutkind JS; Miskimins WK; Lee JH
    Neoplasia; 2013 Jun; 15(6):620-30. PubMed ID: 23730210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual induction of apoptotic and autophagic cell death by targeting survivin in head neck squamous cell carcinoma.
    Zhang L; Zhang W; Wang YF; Liu B; Zhang WF; Zhao YF; Kulkarni AB; Sun ZJ
    Cell Death Dis; 2015 May; 6(5):e1771. PubMed ID: 26018732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The dual mTORC1 and mTORC2 inhibitor AZD8055 inhibits head and neck squamous cell carcinoma cell growth in vivo and in vitro.
    Li Q; Song XM; Ji YY; Jiang H; Xu LG
    Biochem Biophys Res Commun; 2013 Nov; 440(4):701-6. PubMed ID: 24103749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MACC1 regulates PDL1 expression and tumor immunity through the c-Met/AKT/mTOR pathway in gastric cancer cells.
    Tong G; Cheng B; Li J; Wu X; Nong Q; He L; Li X; Li L; Wang S
    Cancer Med; 2019 Nov; 8(16):7044-7054. PubMed ID: 31557409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemopreventive and chemotherapeutic actions of mTOR inhibitor in genetically defined head and neck squamous cell carcinoma mouse model.
    Sun ZJ; Zhang L; Hall B; Bian Y; Gutkind JS; Kulkarni AB
    Clin Cancer Res; 2012 Oct; 18(19):5304-13. PubMed ID: 22859719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protein kinase D3 regulates the expression of the immunosuppressive protein, PD‑L1, through STAT1/STAT3 signaling.
    Cui B; Chen J; Luo M; Wang L; Chen H; Kang Y; Wang J; Zhou X; Feng Y; Zhang P
    Int J Oncol; 2020 Apr; 56(4):909-920. PubMed ID: 32319563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Curcumin inhibits carcinogen and nicotine-induced Mammalian target of rapamycin pathway activation in head and neck squamous cell carcinoma.
    Clark CA; McEachern MD; Shah SH; Rong Y; Rong X; Smelley CL; Caldito GC; Abreo FW; Nathan CO
    Cancer Prev Res (Phila); 2010 Dec; 3(12):1586-95. PubMed ID: 20851953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of tumor growth driven by PIK3CA and HPV oncogenes by targeting mTOR signaling with metformin in oral squamous carcinomas expressing OCT3.
    Madera D; Vitale-Cross L; Martin D; Schneider A; Molinolo AA; Gangane N; Carey TE; McHugh JB; Komarck CM; Walline HM; William WN; Seethala RR; Ferris RL; Gutkind JS
    Cancer Prev Res (Phila); 2015 Mar; 8(3):197-207. PubMed ID: 25681087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. mTOR inhibition as an adjuvant therapy in a metastatic model of HPV+ HNSCC.
    Coppock JD; Vermeer PD; Vermeer DW; Lee KM; Miskimins WK; Spanos WC; Lee JH
    Oncotarget; 2016 Apr; 7(17):24228-41. PubMed ID: 27015118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PDK1 Mediates
    Sambandam V; Frederick MJ; Shen L; Tong P; Rao X; Peng S; Singh R; Mazumdar T; Huang C; Li Q; Pickering CR; Myers JN; Wang J; Johnson FM
    Clin Cancer Res; 2019 Jun; 25(11):3329-3340. PubMed ID: 30770351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel IFNα-induced long noncoding RNA negatively regulates immunosuppression by interrupting H3K27 acetylation in head and neck squamous cell carcinoma.
    Ma H; Chang H; Yang W; Lu Y; Hu J; Jin S
    Mol Cancer; 2020 Jan; 19(1):4. PubMed ID: 31907020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma.
    Ku BM; Yi SY; Koh J; Bae YH; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Oncotarget; 2016 Mar; 7(12):14803-13. PubMed ID: 26909611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.